2020 American Transplant Congress » Kidney Immunosuppression: Desensitization

Date: Saturday, May 30, 2020

Time: 3:15pm-4:45pm

Location: Virtual

Session Type: Oral Abstract Session

Meeting: 2020 American Transplant Congress

3:15pm-3:27pm: BAFF Inhibition to Prevent Antibody Rebound Following Proteasome Inhibitor-Based Desensitization: A Randomized, Controlled Trial

S. Tremblay¹, A. Rike-Shields², A. Govil¹, M. Cardi³, P. Brailey¹, R. Alloway¹, E. Woodle¹

3:27pm-3:39pm: Navigating Through IgM Antibodies in Deceased Donor Kidney Transplants from A2/A2B Donors to B Recipients

M. Kueht, A. Gamilla-Crudo, S. Hussain, R. Kulkarni, J. Fair, H. Stevenson-Lerner, M. Mujtaba

3:39pm-3:51pm: Outcomes of HLAi Transplant in CPRA 98-100 after Desensitization: Single Center Experience

A. Vo¹, E. Huang¹, M. Haas², S. Williamson¹, C. Meyers¹, A. Peng¹, R. Najjar¹, S. Sethi¹, N. Ammerman¹, K. Lim¹, M. Gillespie¹, S. C. Jordan¹

3:51pm-4:03pm: Carfilzomib-Based Desensitization: Effects on HLA, Non-HLA, Auto, and Antiviral Antibodies

S. Tremblay¹, E. Portwood¹, A. R. Shields², R. R. Alloway¹, P. A. Brailey¹, E. Woodle¹

4:03pm-4:15pm: Anti-HLA IgM Antibodies are Unaffected by Imlifidase (IdeS) Treatment

A. Runström¹, R. Bockermann¹, K. Sjöholm¹, K. M. Roupé¹, Å. Schiött¹, L. Winstedt¹, C. Kjellman¹, T. Lorant²

4:15pm-4:27pm: Evaluation of the Safety and Tolerability of Clazakizumab® as a Desensitization Agent in Highly-HLA Sensitized ESRD Patients (NCT03380962): 12m Follow-Up

A. A. Vo¹, N. Ammerman¹, E. Huang¹, M. Toyoda², S. Ge², A. Peng¹, R. Najjar¹, S. Williamson¹, C. Meyers¹, S. Sethi¹, K. Lim¹, J. Choi¹, S. C. Jordan¹

4:27pm-4:39pm: Peak DSA Levels Pre-Transplant but Not at Transplant Predict Graft Survival

A. Y. Choi¹, D. Olaso¹, T. Risoli Jr², M. Kuchibhatla², Z. Fitch³, R. Schmitz³, P. M. Schroder³, A. Jackson³, M. Manook³, J. Yoon³, A. B. Farris⁴, J. Kwun³, S. J. Knechtle³

« View all sessions from the 2020 American Transplant Congress